Other Biopharmaceuticals

Eisai Co., Ltd.

As of November 11, 2025, the interventional oncology market is projected to grow to approximately $4.38 billion by the year 2030, with a Compound Annual Growth Rate (CAGR) of 8.55% between 2025 and 2030. These figures were reported in a recent study conducted by Grand View Research, Inc. The substantial growth in the market is mainly driven by...

Unusual Whales

Global interventional oncology market to hit $4.38B by 2030, growing at 8.55% annually from 2025, per Grand View Research.

PRAX

QURE

MDGL

Biotech stocks are rebounding after a four-year slump, with the SPDR S&P Biotech ETF up 25% this year. Analysts attribute this resurgence to positive drug trial results, increased mergers and acquisitions, successful drug launches, falling interest rates, easing tariff risks, reduced drug-price control threats, and a stabilizing FDA environment. Notable stocks include UniQure, Praxis Precision Medicines, and Madrigal Pharmaceuticals, which have seen significant gains. Experts believe the sector's strength will continue, making it a favorable time for investors to enter the market.

Dow Jones

Praxis Precision Medicines

Uniqure

Madrigal Pharma

Biotech stocks are coming back. Here's what's driving the sector higher.

On November 7, 2025, a study revealed a discrepancy between two prevalent tests for kidney function could suggest a heightened likelihood of kidney failure, heart issues, and mortality. The research indicated that assessing both biomarkers could uncover a larger number of individuals with impaired kidney function, potentially leading to early detection and intervention to prevent adverse health outcomes.

Disagreement in two kidney function tests can predict higher risk for kidney failure, heart disease, and death, suggesting a need for better assessments. (Characters: 151)

On November 7, 2025, it was reported that 1 out of every 7 adults is projected to experience kidney disease throughout their lifetime. This highlights the urgent necessity for early detection, education, and advancements in kidney healthcare. The Kidney Health campaign by Mediaplanet has been introduced, coinciding with Kidney Week, to address this pressing issue and bring together top experts in the field.

Alonzo Mourning partners to raise awareness for kidney disease, highlighting 1 in 7 adults will develop it in their lifetime.

4523

Nov 7 (Reuters) - Eisai Co Ltd (4523.T) :* EISAI CO LTD - NOTICE OF THE SETTLEMENT OF PATENT INFRINGEMENT LITIGATION RELATED TO LENVATINIB IN THE U.S. Source text: Further company coverage: (4523.T)

Reuters

Eisai Co Ltd - Notice Of The Settlement Of Patent Infringement Litigation Related To Lenvatinib In The U.S.

Cardiovascular diseases are the primary cause of death globally, with an estimated 15 bacterial species associated with coronary artery disease (CAD) identified by researchers in Seoul. CAD remains a prevalent heart condition, with the exact mechanisms involving gut microbes largely undetermined.

New study in Seoul finds 15 gut bacterial species linked to CAD – a leading cause of death worldwide.

Ben-Gurion University of the Negev in Israel recently announced that researchers at the university have discovered a type of immune cell that may help delay aging, providing new ideas for the diagnosis and treatment of age-related diseases. The announcement stated that a previously underappreciated subset of CD4 helper T cells accumulates with age. Initially, researchers did not realize its significance, but a study in Japan on centenarians showed that their immune systems are filled with this subset of helper T cells. (Xinhua News Agency)

Wallstreetcn

New research discovers immune cells that may delay aging

HMI-115 has shown a notable improvement in endometriosis-induced pain, with Dysmenorrhea NRS scores reducing by 41.57%, 34.72%, and 27.35% in the three different dosage groups. Moreover, all dosage groups experienced a decrease in non-menstrual pelvic pain NRS scores, indicating sustained effectiveness of HMI-115 treatment.

HMI-115 shows promising results in treating endometriosis; Dysmenorrhea NRS scores decreased by 41.57%, 34.72%, 27.35%.

According to projections, the rheumatoid arthritis sector is anticipated to undergo transformations between 2025 and 2034. This shift is primarily attributed to the introduction of new treatment options, including rabeximod by Cyxone, TAS5315 by Taiho Pharmaceutical, as well as AZD1163 and AZD6912 by AstraZeneca. Additionally, Ocadusertib from Eli Lilly and Company and R-2487 by Rise are expected to contribute to these changes.

Eli Lilly

Rheumatoid arthritis market to surge by 2034 with new therapies like rabeximod, TAS5315, AZD1163, AZD6912, Ocadusertib, R-2487.

PLTR

Palantir (PLTR) reported strong quarterly earnings, surpassing Wall Street expectations, yet its stock fell 7-8% post-announcement. This trend is seen across various AI stocks as investors take profits after significant gains. Capital is shifting towards the biotech sector, which is poised to benefit from AI advancements in drug development and personalized medicine. Biotech stocks are currently undervalued compared to AI stocks, presenting a potential growth opportunity as investor sentiment shifts. The article emphasizes the importance of recognizing market rotations and suggests biotech as a promising investment destination.

- Palantir reported strong quarterly earnings, exceeding Wall Street expectations, yet its stock fell by 7-8% after a brief rise, reflecting a trend among high-flying AI stocks.  
- Investors are taking profits from these stocks, which have seen significant gains, and are now looking towards the biotech sector, which is poised to benefit from AI advancements in drug development.  
- Biotech stocks, currently undervalued compared to AI stocks, present opportunities for growth as they integrate AI technologies, potentially leading to increased profits and investor interest.

Talkmarkets

Palantir Tech

The AI Revolution Isn’t Over… It’s Moving Here

The biomarker industry is experiencing a surge in partnerships driven by the demand for precision medicine and early disease detection. A recent BCC Research study highlights strategic transactions, including licensing and acquisitions, as companies invest in R&D, particularly in oncology and immunology. The rise in chronic diseases, such as cancer and COVID-19, necessitates early diagnosis and effective treatments. Technological advancements in genomics and imaging are enhancing biomarker discovery and validation, fueling market growth.

Biomarker deals are on the rise, reflecting the growing innovation in the industry. The surge in demand for precision medicine, early disease detection, and targeted therapies has led to increased partnerships. Factors such as rising chronic and infectious diseases drive market growth in biomarker-related partnerships. Technologies like genomics and advanced imaging play a crucial role in discovering and validating biomarkers.

BIIB

Biogen and Eisai have received FDA approval for LEQEMBI® IQLIK™, a subcutaneous injection for at-home maintenance treatment of early Alzheimer’s disease. This allows patients who completed 18 months of intravenous treatment to switch to a weekly injection or continue with monthly IV infusions. The approval aims to enhance access and reduce treatment burden for eligible patients in the U.S.